FDA Advisory Panel Recommends Loosening Restrictions on Six Popular Experimental Peptides for Compounding Pharmacies

An FDA advisory panel recently recommended that six of the seven experimental peptides it reviewed be made legally available for compounding pharmacies to produce. This move would allow specialty pharmacies to create custom medications without the standard FDA approval process, which typically requires rigorous human clinical trials. The six peptides—BPC-157, KPV, TB-500, Epitalon, Semax, and MOTS-c—are currently popular in the wellness and longevity space, often promoted by influencers and podcasters. Health Secretary Robert F. Kennedy Jr. and the peptide industry heavily influenced the recommendation, which seeks to move these substances out of the "significant safety risk" category. However, agency scientists expressed concerns regarding the lack of robust human data, warning that the enthusiasm for these drugs often outpaces the clinical evidence. While the administration announced the committee's recommendation, the final decision rests with the FDA. If approved, the administration will allow consumers to access these unproven compounds through less-regulated pharmacies, potentially creating a multibillion-dollar market for telehealth and pharmacy companies.

Sources

• NPR
  What would it take to get peptides on the shelf?
• The Guardian
  ‘It’s a peptide wild west’: how RFK Jr is clearing way for a market of untested drugs
• forbes.com
  On Peptides, FDA Staff Scientists At Odds With Advisory Panel
• San Francisco Chronicle
  ‘I would never do this’: What scientists want you to know about peptide injections